Twitter Beğeni Hilesi

Fantastic Atypical Alzheimer's Disease PIA organized featured research symposium covering language and visual presentations, proteomics, lipodomics and digital pathology. Thanks to the speakers Ismael Calandri Keir Yong Betty Tijms Sarah Dunlop + chair/organizer Baayla DC Boon.

The reduction of Tau PET signal by MAPT ASO BIIB080 was associated with subtle favorable cognitive outcomes in this small sample. Promising! #AAIC24

Exciting plenary by Timothy Miller on antisense oligonucleotide therapies for ALS, AD and primary 4R-tauopathies. #AAIC24

Really enjoyed Alzheimercentrum Amsterdam colleague HenneHolstege’s plenary on how centinarions can inform us about AD, such an impressive body of work. #AAIC24

Great session on pathological, post-mortem & ante-mortem MRI, and FDG PET signatures of LATE, as well as novel biofluid and PET measures of TDP pathology. #AAIC24

Terrific basic science session on tau filaments, protection against tau and tau neurotoxicity in AD, FTD and CTE. #AAIC24

Modeling the relationship between Lecanemab indiced amyloid removal and change on the CDR-SOB. #AAIC24

Lecanemab attenuates the rate of tau (PET) accumulation. #AAIC24

Nick Fox making the case that excess brain volume loss associated with Lecanemab (or other effective mAB’s) is associated with the removal of “space-occupying” structures, as amyloid plaques occupy ~6-8% of the cortex in autopsy studies. #AAIC24

Charlotte Teunissen (Charlotte Teunissen) showed the dynamics of CSF and plasma protein changes during the open-label extension (and the gap period) of Clarity AD. #AAIC24

Blood Biomarkers to Detect Alzheimer Disease in Primary Care and Secondary Care This work led by Sebastian Palmqvist Gemma Salvadó & Oskar Hansson represents the next key step in the development and implementation of blood-based biomarkers. Very happy to be part of this team. Link to

ARIA: Bench to bedside and back. #AAIC24

Wonderful plenary on the role of synaptic oligomeric tau in AD and PSP by Prof Tara Spires-Jones. #AAIC24

Great to learn from Ricardo F. Allegri about their impressive body research but also all the challenges that needs/needed to be overcome in low- and middle-income countries. #AAIC24

Last presentation from the group by Sophie Mastenbroek on four biomarker defined disease progression profiles (“AD”, “mixed AD+vascular”, “vascular” & “alfa-syn”). #AAIC24 BioFINDER Alzheimercentrum Amsterdam w/Lyduine Collij, Jake Vogel & Oskar Hansson.

On my way back to Amsterdam after an excellent #AAIC24 in Philly.

The figure we all have to learn by heart: The updated Lancet Commission on potentially modifiable risk factors for dementia. #AAIC24

Time for an update! Ismael Calandri Gill Livingston Regina Paradela Lucía Crivelli Ricardo F. Allegri Claudia Suemoto MD PhD MSc

The BeyeOMARKER study design paper is out! In BeyeOMARKER we will screen 700 individuals with plasma p-tau217 at an eye clinic, and further characterize 150 of them with Amyloid & Tau PET, MRI, retinal imaging and cognitive & cortical vision assessment. Thanks to the great team

Proteomic changes in Alzheimer disease associated with progressive Aβ plaque and tau tangle pathologies Very elegant work from BioFINDER, led by Alexa Pichet Binette, Jake Vogel & Oskar Hansson. Link at Nature Neuroscience > nature.com/articles/s4159…